[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Seoul National University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":137},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,82,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100640428","effects-of-postprandial-walking-and-resistance-snacking-on-glucose-responses-in-adults-with-metabolic-syndrome-100640428",false,"NCT07620886","Effects of Postprandial Walking and Resistance Snacking on Glucose Responses in Adults With Metabolic Syndrome","Effects of Postprandial Walking and Brief Resistance Exercise Snacks on Continuous Glucose and Heart Rate Variability Responses in Adults With Metabolic Syndrome and Prediabetes: A Randomized Crossover Trial","BITE","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Adults aged 40 to 65 years\n* Presence of metabolic syndrome\n* Fasting glucose of 100 mg\u002FdL or higher or HbA1c of 5.7% or higher\n* Not regularly engaged in structured exercise training, defined as less than 150 minutes per week during the past year\n* Able to consume the standardized study meals\n* Able to wear a continuous glucose monitor and a chest strap heart rate monitor\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* History of major cardiovascular, cerebrovascular, respiratory, renal, hepatic, neurological, or other severe medical conditions that may affect study participation.\n* Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg.\n* Current use of medications associated with a high risk of hypoglycemia, such as insulin or sulfonylureas.\n* Initiation or dose change of insulin or oral glucose-lowering medications within the past 3 months.\n* Initiation or dose change of medications for hypertension, dyslipidemia, or diabetes within the past 3 months.\n* Musculoskeletal, neurological, or orthopedic conditions that limit safe participation in walking or body-weight resistance exercise, including severe knee, hip, back, or ankle pain.\n* Regular participation in moderate-to-vigorous exercise of 150 minutes or more per week during the past year.\n* Difficulty consuming the standardized study meals, including food allergy, dietary restrictions, or severe gastrointestinal symptoms.\n* Difficulty wearing a continuous glucose monitor or history of severe skin irritation or allergy to adhesive sensors.\n* Difficulty wearing a chest strap heart rate monitor or skin problems at the chest strap site.\n* Pregnancy or planned pregnancy.\n* Acute illness, infection, surgery, or hospitalization within the past month.\n* Current participation in another interventional study.\n* Any condition judged by the investigator to make participation unsafe or inappropriate.\n\nExclusion Criteria:\n\n\\-","ALL","40 Years","65 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will examine whether light physical activity after meals can improve 24-hour glucose responses in adults with metabolic syndrome and prediabetes.\n\nParticipants will complete three experimental conditions in a randomized crossover order: prolonged sitting, 15 minutes of postprandial walking, and brief resistance exercise snacks consisting of squats and calf raises performed every 20 minutes during the postprandial period. Continuous glucose monitoring will be used to assess 24-hour glucose responses, and heart rate variability will be measured during the 2-hour postprandial period to evaluate acute autonomic responses.\n\nThe main outcome is 24-hour mean glucose derived from continuous glucose monitoring.",[28,29],"Metabolic Syndrome","Prediabetes",[31,32,33,34,35,29,36],"Continuous glucose monitoring","Postprandial glucose","Exercise snack","Resistance exercise","Heart rate variability","Metabolic syndrome","NOT_YET_RECRUITING","2026-05-27",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":22},"2026-06-15",{"date":45,"type":22},"2026-10",{"name":47,"class":48},"Seoul National University","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100605269","refractory-breathlessness-in-copd-100605269","NCT07160322","Refractory Breathlessness in COPD","Prognosis and Clinical Outcomes of Refractory Dyspnea in Chronic Obstructive Pulmonary Disease: Prospective Observational Study","RB-COPD","Inclusion Criteria:\n\n* Adults (≥ 18 years) diagnosed with chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 criteria:\n* Presence of COPD risk factors (e.g., smoking history, occupational exposure, genetic predisposition).\n* Typical symptoms such as dyspnea, cough, or sputum production.\n* Post-bronchodilator FEV1\u002FFVC \\\u003C 0.70.\n* Regular outpatient follow-up at the respiratory clinic.\n* Received LABA\u002FLAMA combination therapy for at least 3 months prior to enrollment.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Poor adherence to LABA\u002FLAMA therapy (medication possession rate \\\u003C 50%) or refusal of treatment.\n* Inability or unwillingness to comply with scheduled visits, examinations, or follow-up procedures.\n* Presence of severe comorbid conditions expected to significantly affect prognosis, including:\n\n  * End-stage diseases with life expectancy \\\u003C 1 year.\n  * Terminal malignancies receiving hospice or palliative care.\n* Any condition that, in the opinion of the investigator, would interfere with study participation or data reliability.","18 Years","100 Years",{"count":60,"type":22},730,"5 Years","OBSERVATIONAL","This study aims to investigate the prognosis and clinical outcomes of patients with chronic obstructive pulmonary disease (COPD) who continue to experience refractory dyspnea despite treatment with long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA). The research will prospectively follow a cohort of patients to identify clinical factors, lung function parameters, imaging features, and cardiovascular indicators associated with poor treatment response. By comparing these patients with those who show symptom improvement, the study seeks to determine predictors of exacerbations, lung function decline, and mortality. Findings are expected to guide the development of targeted strategies to improve the management of refractory dyspnea in COPD.",[65],"COPD",[67,68,69,70,71],"Chronic Obstructive Pulmonary Disease (COPD)","Refractory Breathlessness","Persistent Dyspnea","Treatment Resistance","Unresponsive to Therapy","RECRUITING","2025-08-29",{"date":75,"type":41},"2025-09-08",{"date":77,"type":41},"2024-04-11",{"date":79,"type":22},"2031-12-31",{"name":47,"class":48},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":57,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":81},"100570165","effectiveness-and-implementation-of-mobile-health-platform-for-medication-management-and-e-labeling-edrugsafe-100570165","NCT06703697","Effectiveness and Implementation of Mobile Health Platform for Medication Management and E-Labeling (eDrugSafe)","Evaluating the Effectiveness and Implementation of Mobile Health Platform for Medication Management and E-Labeling (eDrugSafe): a Cluster Randomized Trial","Inclusion Criteria:\n\n1. Adults aged 18 to 79 years.\n2. Individuals who can speak and understand Korean.\n3. Possession of a personal electronic device capable of accessing mobile applications and web services over wireless internet (bring participants' own device, BYOD).\n4. Patients taking three or more medications with at least one medication prescribed for 28 days or longer.\n5. Individuals who have provided direct consent to participate in the study.\n\nExclusion Criteria:\n\n1. Individuals using any mobile web platform other than eDrugSafe for medication safety information purposes after enrollment.\n2. Individuals who do not consent to participate in the study or who withdraw their consent.",true,"79 Years",{"count":92,"type":22},360,[25],"The goal of this cluster randomized trial is to learn if eDrugSafe, a mobile web platform for drug electronic labeling (e-labeling) and medication management, can improve medication adherence and self-efficacy in adults who take multiple medications. This study will also assess whether eDrugSafe is feasible and acceptable for use in real clinical settings, especially in local pharmacies.\n\nThe main questions it aims to answer are:\n\n* Can eDrugSafe improve medication adherence, self-efficacy, and quality of life for adults taking multiple medications and reduce hospitalizations?\n* Is eDrugSafe acceptable and feasible for implementing drug e-labeling and supporting medication management in community settings?\n\nResearchers will compare eDrugSafe to usual care (traditional paper methods) to see if eDrugSafe is effective in supporting adults who take multiple medications, and if it can be feasibly implemented in local pharmacies.\n\nParticipants will:\n\n* Visit a local pharmacy randomly assigned to use eDrugSafe or traditional care methods and decide if they wish to join the study.\n* Use either eDrugSafe to access medication information and manage their medication history, or receive usual care with paper-based methods, for 6 months.\n* Complete surveys at the start of the study, at 3 months, and at 6 months to measure effectiveness and implementation outcomes.",[96,97,98],"Mobile Health","Medication Management","Drug Labelling",[96,97,100,101,102,103,104,105],"Drug E-label","electronic labeling","hybrid study","implementation","cluster randomized trial","Electronic Medicinal Product Information (ePI)","2024-11-25",{"date":108,"type":41},"2024-11-27",{"date":110,"type":41},"2024-08-12",{"date":112,"type":22},"2025-07-31",{"name":47,"class":48},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100552245","thoracic-sympathetic-ganglion-block-with-botulinum-toxin-type-a-100552245","NCT06470581","Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A","Clinical Effect of Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A in Patients With Upper Extremity Complex Regional Pain Syndrome: A Prospective Randomized, Double-blind, and Comparative Clinical Trial","Inclusion Criteria:\n\n1. aged 19-80 years\n2. Diagnosed with a complex regional pain syndrome (type 1 or 2) in unilateral upper extremity\n3. 11-point numerical-rating-scale (NRS) pain score of 4 or higher in upper extremity\n4. Temperature increase at diagnostic thoracic sympathetic ganglion block\n5. Patients taking medication stably (without change in dosage\u002Frecipe) for more than 4 weeks prior to administration\n\nExclusion Criteria:\n\n1. Refusal of the patient\n2. Vascular disease at upper extremity\n3. previous thoracic sympathetic neurolysis (thermocoagulation, chemical neurolysis)\n4. coagulopathy\n5. systemic infection or local infection at thoracic puncture site\n6. significant deformity at thoracic spine\n7. neoplasm\n8. known allergic reaction with amide type local anesthetics\n9. cognitive dysfunction (not understanding of numerical-rating-scale)\n10. known allergic reaction with botulinum toxin\n11. pregnant or feeding women\n12. If the patient has participated in another clinical trial within 30 days before screening, or if passed no longer than 5-fold half-life of the clinical trial drug of the participating clinical trial","19 Years","80 Years",{"count":124,"type":22},78,[25],"Thoracic sympathetic ganglion block is a percutaneous procedure that paralyzes the action of sympathetic nerves transiently by injecting a local anesthetic around the ganglion. It is performed to diagnose and treat sympathetically maintained pain in phantom limb pain or complex reginal pain syndrome patient. The temperature of the affected arm is often lower than that of the opposite side. As a result of the procedure, the patient may experience sympathetic pain relief, such as coldness, stinging, numbness of the upper extremity. If the procedure does not last long, repetitive block or chemical neurolysis or radiofrequency thermocoagulation for the sympathetic ganglion is performed.\n\nHowever, even though in rare cases, chemical neurolysis is known to cause permanent plexus injury radiofrequency thermocoagulation is known to be less successful than chemical neurolysis because it is difficult to identify and stimulate the exact location of the ganglion. Therefore, it is expected that there will be a benefit to the patients if there is a procedure with long-lasting and avoiding injury.\n\nRecently, it has been reported that botulinum toxin (BTX) has been successfully used for the treatment of pain disorders. BTX plays a role with blocking the secretion of acetylcholine from the cholinergic nerve endings. Therefore, the use of BTX is expected to prolong the effect of neural blockade because pre-ganglia sympathetic nerves are cholinergic. It is also known that the action of BTX is not permanent and BTX does not exhibit cytotoxicity or neurotoxicity. Therefore, Botulinum toxin type A (BTA) is recommended for the treatment of migraine, myofascial pain syndrome, and neuropathic pain accompanied by allodynia. This study would like show whether thoracic sympathetic ganglion block using BTA has a longer duration than conventional local anesthesia by using prospective randomized, double-blind, parallel group, and comparative clinical trials.",[128],"Complex Regional Pain Syndromes","2024-06-24",{"date":131,"type":41},"2024-06-26",{"date":133,"type":22},"2024-07-01",{"date":135,"type":22},"2027-04-25",{"name":47,"class":48},""]